PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
1
Istituto di Patologia Generale, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy
2
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy
3
Scientific Vice-Direction, Fondazione Policlinico Universitario “A. Gemelli”–I.R.C.C.S., Largo Francesco Vito 1-8, 00168 Rome, Italy
*
Authors to whom correspondence should be addressed.
†
These authors equally contributed.
Cancers 2019, 11(8), 1076; https://doi.org/10.3390/cancers11081076
Received: 2 July 2019 / Revised: 24 July 2019 / Accepted: 26 July 2019 / Published: 30 July 2019
(This article belongs to the Special Issue PTEN: A Multifaceted Tumor Suppressor)
PTEN is one of the most frequently inactivated tumor suppressor genes in cancer. Loss or variation in PTEN gene/protein levels is commonly observed in a broad spectrum of human cancers, while germline PTEN mutations cause inherited syndromes that lead to increased risk of tumors. PTEN restrains tumorigenesis through different mechanisms ranging from phosphatase-dependent and independent activities, subcellular localization and protein interaction, modulating a broad array of cellular functions including growth, proliferation, survival, DNA repair, and cell motility. The main target of PTEN phosphatase activity is one of the most significant cell growth and pro-survival signaling pathway in cancer: PI3K/AKT/mTOR. Several shreds of evidence shed light on the critical role of PTEN in normal and cancer stem cells (CSCs) homeostasis, with its loss fostering the CSC compartment in both solid and hematologic malignancies. CSCs are responsible for tumor propagation, metastatic spread, resistance to therapy, and relapse. Thus, understanding how alterations of PTEN levels affect CSC hallmarks could be crucial for the development of successful therapeutic approaches. Here, we discuss the most significant findings on PTEN-mediated control of CSC state. We aim to unravel the role of PTEN in the regulation of key mechanisms specific for CSCs, such as self-renewal, quiescence/cell cycle, Epithelial-to-Mesenchymal-Transition (EMT), with a particular focus on PTEN-based therapy resistance mechanisms and their exploitation for novel therapeutic approaches in cancer treatment.
View Full-Text
Keywords:
cancer stem cells; PTEN; therapy resistance; targeted therapy
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Luongo, F.; Colonna, F.; Calapà, F.; Vitale, S.; Fiori, M.E.; De Maria, R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers 2019, 11, 1076. https://doi.org/10.3390/cancers11081076
AMA Style
Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers. 2019; 11(8):1076. https://doi.org/10.3390/cancers11081076
Chicago/Turabian StyleLuongo, Francesca; Colonna, Francesca; Calapà, Federica; Vitale, Sara; Fiori, Micol E.; De Maria, Ruggero. 2019. "PTEN Tumor-Suppressor: The Dam of Stemness in Cancer" Cancers 11, no. 8: 1076. https://doi.org/10.3390/cancers11081076
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit